Literature DB >> 30675957

Chronic obstructive pulmonary disease (COPD) among opioid-dependent patients in agonist treatment. A diagnostic study.

Thomas Grischott1, Luis Falcato2, Oliver Senn1, Milo Alan Puhan3, Philip Bruggmann1,2.   

Abstract

AIMS: To estimate the prevalence of chronic obstructive pulmonary disease (COPD) and related risk factors in people in opioid agonist treatment (OAT), to compare airflow limitation severity and age-specific COPD prevalence rates with those in the general population, and to assess the OAT patients' willingness to adopt life-style changes and to use therapeutic offers for COPD management.
DESIGN: Cross-sectional study in a random sample of OAT patients.
SETTING: Out-patient centres for substance addiction medicine in Zurich, Switzerland. PARTICIPANTS: A total of 125 participants, recruited from November 2016 to April 2017 through invitation letters followed by phone or personal contact. MEASUREMENTS: Standardized questionnaires about drug use, smoking habits and medical history, completed during face-to-face interviews or from medical records. Spirometry without and-depending on the result-with bronchodilation.
FINDINGS: Almost one-third [30.3%; 95% confidence interval (CI) = 22.6-39.0%] of the 119 participants with valid spirometry tests were diagnosed with COPD. Among males aged 30-59 years, the age-adjusted prevalence of at least moderate airflow limitation (GOLD grade ≥ 2) was 2.4 (95% CI = 1.3-4.4) times as high as in the ever-smoking Swiss population in the same age group. Smoking tobacco (92.0%) and substance inhalation (cannabis = 97.6%, cocaine = 69.6%, heroin = 68.0%) were highly prevalent among all participants. The participants expressed considerable interest in life-style changes and use of therapeutic offers for COPD management, with smoking cessation being least (20.2% of tobacco smokers interested) and pharmacological treatment to alleviate COPD symptoms most popular.
CONCLUSIONS: In Switzerland, COPD prevalence and multiple risk factors for COPD appear to be high among people in OAT compared with the general population. Individuals in OAT appear to develop COPD at a younger average age compared with the general population and are open to life-style changes and other COPD management approaches.
© 2019 Society for the Study of Addiction.

Entities:  

Keywords:  Case finding; chronic obstructive pulmonary disease; opioid agonist treatment; opioid dependence; opioid substitution treatment; people with opioid use disorder; screening; spirometry

Mesh:

Substances:

Year:  2019        PMID: 30675957     DOI: 10.1111/add.14559

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  2 in total

1.  Blockade of 5-Hydroxytryptamine 2A Receptor Attenuates Precipitation of Naloxone-Induced Withdrawal Symptoms in Opioid-Exposed Mice.

Authors:  Bing Li; Junyu Jiang; Li Zhou; Xinrong Tao; Qixian Sun; Jiaxin Liu; Yang Liu; Gang Pang
Journal:  Front Behav Neurosci       Date:  2022-02-09       Impact factor: 3.558

2.  Golden opportunity for intervention? Identifying vitamin D deficiency in patients with substance use disorders in hospital.

Authors:  E Naomi Smith; Siobhan Gee; Gerri O'Brien; Pitchy-Ann Vicente; Rosemary Griffith; Rina Patel; Joshua Stapleton; Emily Finch; Naina Shah; Fiona Gaughran; David Taylor; John Strang; Nicola J Kalk
Journal:  BMJ Open Qual       Date:  2022-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.